biopharma-reporter2h
Serious adverse event causes problems for Neurogene’s Rett gene therapy
A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...
biopharma-reporter5h
FDA approves first-ever gene therapy to be directly administered to the brain
PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...
biopharma-reporter5d
Promising early Parkinson’s immunotherapy results for AC Immune
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
biopharma-reporter5d
SEKISUI Diagnostics completes £15.7M expansion to boost biopharma manufacturing capacity
New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
biopharma-reporter5d
Alentis raises $181 million to advance ADCs to the clinic
The Series D financing will support the clinical development of two ADCs.
biopharma-reporter7d
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its future in doubt. AbbVie acquired Cerevel Therapeutics and the rights to ...